{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:56:37Z","timestamp":1790722597379,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41391-026-01128-1","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T08:39:51Z","timestamp":1781253591000},"page":"875-884","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between concomitant ACEI\/ARBs use and survival of patients with prostate cancer receiving abiraterone acetate: A post-hoc analysis of two randomized trials"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5612-258X","authenticated-orcid":false,"given":"Junliang","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5319-4633","authenticated-orcid":false,"given":"Xinyang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1804-6952","authenticated-orcid":false,"given":"Zijun","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7699-5743","authenticated-orcid":false,"given":"Zhenyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingbo","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5447-6843","authenticated-orcid":false,"given":"Zhaohui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1795-7242","authenticated-orcid":false,"given":"Yonghong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"1128_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"1128_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100962","volume":"68","author":"M Cai","year":"2023","unstructured":"Cai M, Song XL, Li XA, Chen M, Guo J, Yang DH, et al. Current therapy and drug resistance in metastatic castration-resistant prostate cancer. Drug Resist Updat. 2023;68:100962.","journal-title":"Drug Resist Updat"},{"key":"1128_CR3","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3389\/fonc.2018.00543","volume":"8","author":"MC Hupe","year":"2018","unstructured":"Hupe MC, Hammerer P, Ketz M, Kossack N, Colling C, Merseburger AS. Retrospective Analysis of Patients With Prostate Cancer Initiating GnRH Agonists\/Antagonists Therapy Using a German Claims Database: Epidemiological and Patient Outcomes. Front Oncol. 2018;8:543.","journal-title":"Front Oncol"},{"key":"1128_CR4","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1007\/s00345-014-1439-6","volume":"33","author":"A Carneiro","year":"2015","unstructured":"Carneiro A, Sasse AD, Wagner AA, Peixoto G, Kataguiri A, Neto SA, et al. Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis. World J Urol. 2015;33:1281\u20139.","journal-title":"World J Urol"},{"key":"1128_CR5","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1200\/JCO.2014.59.1792","volume":"33","author":"S O\u2019Farrell","year":"2015","unstructured":"O\u2019Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2015;33:1243\u201351.","journal-title":"J Clin Oncol"},{"key":"1128_CR6","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","volume":"13","author":"K Fizazi","year":"2012","unstructured":"Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13:983\u201392.","journal-title":"Lancet Oncol"},{"key":"1128_CR7","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PFA, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16:152\u201360.","journal-title":"Lancet Oncol"},{"key":"1128_CR8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1161\/HYPERTENSIONAHA.119.14240","volume":"75","author":"FD Fuchs","year":"2020","unstructured":"Fuchs FD, Whelton PK. High Blood Pressure and Cardiovascular Disease. Hypertension. 2020;75:285\u201392.","journal-title":"Hypertension"},{"key":"1128_CR9","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1093\/eurheartj\/ehac395","volume":"44","author":"L Lauder","year":"2023","unstructured":"Lauder L, Mahfoud F, Azizi M, Bhatt DL, Ewen S, Kario K, et al. Hypertension management in patients with cardiovascular comorbidities. Eur Heart J. 2023;44:2066\u201377.","journal-title":"Eur Heart J"},{"key":"1128_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s10147-005-0520-y","volume":"10","author":"H Uemura","year":"2005","unstructured":"Uemura H, Hasumi H, Kawahara T, Sugiura S, Miyoshi Y, Nakaigawa N, et al. Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int J Clin Oncol. 2005;10:405\u201310.","journal-title":"Int J Clin Oncol"},{"key":"1128_CR11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1097\/CEJ.0000000000000269","volume":"26","author":"T Song","year":"2017","unstructured":"Song T, Choi CH, Kim MK, Kim ML, Yun BS, Seong SJ. The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival: a meta-analysis. Eur J Cancer Prev. 2017;26:78\u201385.","journal-title":"Eur J Cancer Prev"},{"key":"1128_CR12","doi-asserted-by":"publisher","first-page":"e0234269","DOI":"10.1371\/journal.pone.0234269","volume":"15","author":"A Siltari","year":"2020","unstructured":"Siltari A, Murtola TJ, Talala K, Taari K, Tammela TLJ, Auvinen A. Antihypertensive drug use and prostate cancer-specific mortality in Finnish men. PLoS One. 2020;15:e0234269.","journal-title":"PLoS One"},{"key":"1128_CR13","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/ijc.31802","volume":"144","author":"EE Santala","year":"2019","unstructured":"Santala EE, Rannikko A, Murtola TJ. Antihypertensive drugs and prostate cancer survival after radical prostatectomy in Finland-A nationwide cohort study. Int J Cancer. 2019;144:440\u20137.","journal-title":"Int J Cancer"},{"key":"1128_CR14","doi-asserted-by":"publisher","first-page":"985","DOI":"10.2147\/OTT.S78836","volume":"8","author":"H Lu","year":"2015","unstructured":"Lu H, Liu X, Guo F, Tan S, Wang G, Liu H, et al. Impact of beta-blockers on prostate cancer mortality: a meta-analysis of 16,825 patients. Onco Targets Ther. 2015;8:985\u201390.","journal-title":"Onco Targets Ther"},{"key":"1128_CR15","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.canep.2014.03.011","volume":"38","author":"CR Cardwell","year":"2014","unstructured":"Cardwell CR, Coleman HG, Murray LJ, O\u2019Sullivan JM, Powe DG. Beta-blocker usage and prostate cancer survival: a nested case-control study in the UK Clinical Practice Research Datalink cohort. Cancer Epidemiol. 2014;38:279\u201385.","journal-title":"Cancer Epidemiol"},{"key":"1128_CR16","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s10552-023-01712-z","volume":"34","author":"N Kazmi","year":"2023","unstructured":"Kazmi N, Valeeva EV, Khasanova GR, Lewis SJ, Plotnikov D. Blood pressure, calcium channel blockers, and the risk of prostate cancer: a Mendelian randomization study. Cancer Causes Control. 2023;34:725\u201334.","journal-title":"Cancer Causes Control"},{"key":"1128_CR17","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138\u201348.","journal-title":"N Engl J Med"},{"key":"1128_CR18","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995\u20132005.","journal-title":"N Engl J Med"},{"key":"1128_CR19","unstructured":"Ryan CJ, Kheoh T, Li J, Molina A, De Porre P, Carles Joan, et al. Prognostic Index Model for Progression-Free Survival in Chemotherapy-Na\u00efve Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Plus Prednisone. Clin Genitourin Cancer. 2017, S1558-7673(17)30211-2."},{"key":"1128_CR20","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1093\/annonc\/mdv594","volume":"27","author":"KN Chi","year":"2016","unstructured":"Chi KN, Kheoh T, Ryan CJ, Molina A, Bellmunt J, Vogelzang NJ, et al. A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel. Ann Oncol. 2016;27:454\u201360.","journal-title":"Ann Oncol"},{"key":"1128_CR21","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.eururo.2023.02.017","volume":"83","author":"S Roy","year":"2023","unstructured":"Roy S, Sun Y, Morgan SC, Wallis CJD, King K, Zhou YM, et al. Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial. Eur Urol. 2023;83:571\u20139.","journal-title":"Eur Urol"},{"key":"1128_CR22","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1002\/cncr.33584","volume":"127","author":"AB Weiner","year":"2021","unstructured":"Weiner AB, Li EV, Desai AS, Press DJ, Schaeffer EM. Cause of death during prostate cancer survivorship: A contemporary, US population-based analysis. Cancer. 2021;127:2895\u2013904.","journal-title":"Cancer"},{"key":"1128_CR23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.tem.2005.07.009","volume":"16","author":"F Deshayes","year":"2005","unstructured":"Deshayes F, Nahmias C. Angiotensin receptors: a new role in cancer?. Trends Endocrinol Metab. 2005;16:293\u20139.","journal-title":"Trends Endocrinol Metab"},{"key":"1128_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan5616","volume":"9","author":"M Pinter","year":"2017","unstructured":"Pinter M, Jain RK. Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. Sci Transl Med. 2017;9:eaan5616.","journal-title":"Sci Transl Med"},{"key":"1128_CR25","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.drudis.2019.03.010","volume":"24","author":"K Regulska","year":"2019","unstructured":"Regulska K, Regulski M, Karolak B, Murias M, Stanisz B. Can cardiovascular drugs support cancer treatment? The rationale for drug repurposing. Drug Discov Today. 2019;24:1059\u201365.","journal-title":"Drug Discov Today"},{"key":"1128_CR26","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/jcp.22209","volume":"225","author":"Y Zhao","year":"2010","unstructured":"Zhao Y, Chen X, Cai L, Yang Y, Sui G, Fu S. Angiotensin II\/angiotensin II type I receptor (AT1R) signaling promotes MCF-7 breast cancer cells survival via PI3-kinase\/Akt pathway. J Cell Physiol. 2010;225:168\u201373.","journal-title":"J Cell Physiol"},{"key":"1128_CR27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","volume":"398","author":"C Sweeney","year":"2021","unstructured":"Sweeney C, Bracarda S, Sternberg CN, Chi KN, Olmos D, Sandhu S, et al. Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2021;398:131\u201342.","journal-title":"Lancet"},{"key":"1128_CR28","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/pros.22505","volume":"72","author":"S Takahashi","year":"2012","unstructured":"Takahashi S, Uemura H, Seeni A, Tang M, Komiya M, Long N, et al. Therapeutic targeting of angiotensin II receptor type 1 to regulate androgen receptor in prostate cancer. Prostate. 2012;72:1559\u201372.","journal-title":"Prostate"},{"key":"1128_CR29","doi-asserted-by":"publisher","first-page":"2580","DOI":"10.1158\/0008-5472.CAN-18-2812","volume":"79","author":"S Li","year":"2019","unstructured":"Li S, Fong KW, Gritsina G, Zhang A, Zhao JC, Kim J, et al. Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer. Cancer Res. 2019;79:2580\u201392.","journal-title":"Cancer Res"},{"key":"1128_CR30","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1200\/JCO.2008.20.0642","volume":"27","author":"G Attard","year":"2009","unstructured":"Attard G, Reid AH, A\u2019Hern R, Parker C, Oommen NB, Folkerd E, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009;27:3742\u20138.","journal-title":"J Clin Oncol"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01128-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01128-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01128-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:00:23Z","timestamp":1790719223000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-026-01128-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1128"],"URL":"https:\/\/doi.org\/10.1038\/s41391-026-01128-1","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study protocol received scientific approval from the YODA Project and was granted an ethical review exemption by the Ethics Committee of Sun Yat-sen University Cancer Center (B2025-140-MS01) due to the use of de-identified data. Written informed consent was obtained from all participants in the original COU-AA-301 and COU-AA-302 trials. The study was conducted in accordance with the Declaration of Helsinki. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}